3 terminated. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Terminated 3 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors Hydroxyurea - Polycythemia Vera | Phase 4 | Terminated | Novartis Pharmaceuticals | 76 | 2023-07-28 | 2026-08-18 |
| Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Ceftolozane / Tazobactam Injection - Pneumonia, Hematologic Malignancy | Phase 4 | Terminated | Weill Medical College of Cornell University | 17 | 2023-01-10 | 2026-01-21 |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Itraconazole, Caspofungin - Hematologic Neoplasms | Phase 4 | Terminated | Xian-Janssen Pharmaceutical Ltd. | 61 | 2016-11-30 | 2019-05-06 |
Bacteremia (1) · Gram-Negative Bacterial Infections (1) · Pneumonia (1) · Polycythemia Vera (1) · Pseudomonas Infections (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Infections (1) · Inflammation (1) · Lung Diseases (1) · Myeloproliferative Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Caspofungin (1) · Hydroxyurea (1) · Itraconazole (1) · ceftolozane, tazobactam drug combination (1)
Novartis Pharmaceuticals (1) · Weill Medical College of Cornell University (1) · Xian-Janssen Pharmaceutical Ltd. (1)
China (1) · Germany (1) · United States (1)
Markus Plate, MD (1)